Protection against West Nile Virus Infection in Mice after Inoculation with Type I Interferon-Inducing RNA Transcripts

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Rodríguez Pulido, Miguel ^a   Martín Acebes, Miguel A ^a,b   Escribano Romero, Estela ^b   Blázquez, Ana Belén ^b   Sobrino, Francisco ^a   Borrego, Belén ^c   Sáiz, Margarita ^a   Saiz, Juan Carlos ^b  

^a CSIC   (Spain)

^b INIA   (Spain)

^c Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; UNTRANSLATED RNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FOOT AND MOUTH DISEASE VIRUS; MOUSE; NEWBORN; NONHUMAN; PROTEIN DOMAIN; RNA STRUCTURE; RNA TRANSCRIPTION; SUCKLING; WEST NILE FLAVIVIRUS;

ANIMALS; GENE EXPRESSION REGULATION, VIRAL; IMMUNITY, INNATE; INTERFERON TYPE I; MICE; RNA, UNTRANSLATED; RNA, VIRAL; WEST NILE FEVER; WEST NILE VIRUS;

ANIMALIA; AVES; EQUIDAE; FLAVIVIRUS; FOOT-AND-MOUTH DISEASE VIRUS; MUS; WEST NILE VIRUS;

EID: 84869104406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049494     Document Type: Article

References (40)

1. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, et al. (2005) Epidemiology and transmission dynamics of West Nile virus disease. Emerging Infect Dis 11: 1167-1173.
2. Martín-Acebes MA, Saiz JC, (2012) West Nile virus: a re-emerging pathogen revisited. World J Virol (in press).
3. Smithburn KC, Hughes TP, Burke AW, Paul JH, (1940) A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 20: 471-492.
4. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, et al. (1999) Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286: 2333-2337.
5. Debiasi RL, Tyler KL, (2006) West Nile virus meningoencepahlitis. Nat Clinic Pract Neurol 2: 264-275.
6. Diamond MS, (2009) Progress on the development of therapeutics against West Nile virus. Antivir Res 83: 214-227.
7. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDAs and RIG-I helicases in the recognition of RNA viruses. Nature 441: 372-376.
8. Kalil AC, Devetten MP, Singh S, Lesiak B, Poage DP, et al. (2005) Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 40: 764-766.
9. Chan-Tack KM, Forrest G, (2005) Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. Scand J Infect Dis 37: 944-946.
10. Lewis M, Amsden JR, (2007) Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy 27: 455-458.
11. Samuel MA, Diamond MS, (2006) Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 80): 9349-9360.
12. Rios JJ, Fleming JG, Bryant UK, Carter CN, Huber JC, et al. (2010) OAS1 polymorphisms are associated with susceptibility to West Nile encephalitis in horses. PLoS One 5: e10537.
13. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, et al. (2009) Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLos Pathog 5: e1000321.
14. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, et al. (2002) A nonsense mutation in the genome encoding 2′-5′-oligoadenylate synthetase/L 1 isoform is associated with West Nile virus susceptibility in laboratory mice. PNAS 99: 11311-11316.
15. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr, (2008) Innate immunity by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454: 523-527.
16. Uzri D, Gehrke L, (2009) Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 83: 4174-4184.
17. Schuessler A, Funk A, Lazear HM, Cooper DA, Torres S, et al. (2012) West Nile virus non-coding subgenomic RNA contributes to viral evasion of type I interferon-mediated antiviral response. J Virol 86: 5708-5718.
18. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, et al. (2005) Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile infection. J Exp Med 43: 1087-1098.
19. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, et al. (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203: 35-40.
20. Daffis S, Samuel MA, Keller BC, Gale M Jr, Diamond MS, (2007) Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog 3: e106.
21. Diamond MS, (2009) Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog 5: e1000452.
22. Diamond MS, Roberts T, Edgil D, Lu B, Ernst J, et al. (2000) Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74: 4957-4966.
23. Morrey JD, Day KW, Julander JG, Blatt LM, Smee FD, et al. (2004) Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 15: 101-109.
24. Rodriguez-Pulido M, Borrego B, Sobrino F, Sáiz M, (2011) RNA structural domains in noncoding regions of the foot-and-mouth disease virus genome trigger immunity in porcine cells and mice. J Virol 85: 6492-6501.
25. Rodriguez-Pulido M, Sobrino F, Borrego B, Sáiz M, (2011) Inoculation of newborn mice with non-coding regions of foot-and-mouth disease virus RNA can induce a rapid, solid and wide-range protection against viral infection. Antiviral Res 92: 500-504.
26. Córdoba L, Escribano-Romero E, Garmendia A, Saiz JC, (2007) Pregnancy increases the risk of mortality in West Nile virus-infected mice. J Gen Virol 88: 476-480.
27. Matín-Acebes MA, Saiz JC, (2011) A West Nile virus mutant with increased resistance to acid-induced inactivation. J Gen Virol 92: 831-840.
28. Alonso-Padilla J, Jiménez de Oya N, Blázquez AB, Escribano-Romero E, Escribano JM, et al. (2011) Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease. Vaccine 29: 1830-1835.
29. Alonso-Padilla J, Jiménez de Oya N, Blázquez AB, Loza-Rubio E, Ecribano JM, et al. (2010) Evaluation of an enzyme-linked immunosorbent assay for detection of West Nile virus infection based on a recombinant envelope protein produced in Trichoplusia ni larvae. J Viral Methods 166: 37-41.
30. Alonso-Padilla J, Loza-Rubio E, Escribano-Romero E, Córdoba L, Cuevas S, et al. (2009) The continuous spread of West Nile virus: seroprevalence in asymptomatic horses. Epidemiol Infect 137: 1163-1168.
31. Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, et al. (2000) Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a Taq Man reverse transcriptase-PCR assay. J Clin Microbiol 38: 4066-4071.
32. Blázquez AB, Saiz JC, (2010) West Nile virus (WNV) transmission routes in the murine model: intrauterine, by breastfeeding, and after cannibal ingestion. Vir Res 151: 240-243.
33. Rubinstein S, Familletti PC, Pestka S, (1981) Convenient assay for interferons. J Virol 37: 7 55-758.
34. Richmond JY, Hamilton LD, (1969) Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). PNAS 64: 81-86.
35. Styer LM, Kent KA, Albright RG, Bennett CJ, Kramer LD, et al. (2007) Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog 3: 1262-1270.
36. Diamond MS, Shrestha B, Mehlhop E, Sitati E, Engle M, (2003) Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16: 259-278.
37. Wang Y, Lobigs M, Lee E, Müllbacher A, (2003) CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77: 13323-13334.
38. Samuel MA, Diamond MS, (2005) Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79: 13350-13361.
39. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28 (2):: 172-176.
40. Pascolo S, (2008) Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 183: 221-235.